IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Expanded access is currently available for this treatment.
Verified December 2014 by University of California, San Francisco
Sponsor:
University of California, San Francisco
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00508963
First received: July 27, 2007
Last updated: December 12, 2014
Last verified: December 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
| Condition | Intervention |
|---|---|
| Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous | Drug: sodium stibogluconate (Pentostam) |
| Study Type: | Expanded Access What is Expanded Access? |
| Official Title: | Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis |
Resource links provided by NLM:
Further study details as provided by University of California, San Francisco:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
Criteria
Inclusion Criteria:
- Biopsy proven new world cutaneous or mucocutaneous leishmania
Exclusion Criteria:
- Prolonged QT
- Liver disease
- Pancreatitis
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508963
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508963
Contacts
| Contact: Jane E Koehler, MA, MD | 415-476-3536 | jkoehler@medicine.ucsf.edu |
Locations
| United States, California | |
| University of CA at San Francisco Hospitals and Clinics | |
| San Francisco, California, United States, 94143 | |
Sponsors and Collaborators
University of California, San Francisco
Investigators
| Principal Investigator: | Brian Schwartz, MD | University of CA at San Francisco |
| Principal Investigator: | Kanade Shinkai, MD | University of CA at San Francisco |
More Information
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT00508963 History of Changes |
| Other Study ID Numbers: |
UCSF Infectious Diseases |
| Study First Received: | July 27, 2007 |
| Last Updated: | December 12, 2014 |
Keywords provided by University of California, San Francisco:
|
New World Cutaneous or Mucocutaneous Leishmaniasis |
Additional relevant MeSH terms:
|
Leishmaniasis Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous Euglenozoa Infections Protozoan Infections Parasitic Diseases Skin Diseases, Parasitic Skin Diseases, Infectious |
Skin Diseases Antimony Sodium Gluconate Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Schistosomicides Antiplatyhelmintic Agents Anthelmintics |
ClinicalTrials.gov processed this record on July 21, 2017